Notas de prensa
- Sin apartado
- General
Amgen to Hold Analyst Call to Discuss Danish Head and Neck Cancer (DAHANCA) 10 Study
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Feb. 16, 2007--Amgen (NASDAQ:AMGN) will hold an analyst call at 1 p.m. Pacific Time today, Feb. 16, 2007, to address inquiries following publication of the interim results of the Danish Head and Neck Cancer (DAHANCA) 10 study. Live audio of the conference call will be simultaneously broadcast over the Internet as a webcast and will be available to members of the news media, investors and the general public.
The webcast of the conference, as with other selected presentations regarding developments in Amgen´s business given by management at certain investor and medical conferences, can be found on Amgen´s Web site, www.amgen.com, under Investors. Information regarding presentation times, webcast availability, and webcast links are noted on Amgen´s Investor Relations Events Calendar. The webcast will be archived and available for replay 72 hours after the event.
About Amgen
Amgen discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science´s promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people´s lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.
CONTACT: Amgen, Thousand Oaks David Polk, 805-447-4613 (media) Arvind Sood, 805-447-1060 (investors)
SOURCE: Amgen
